Modifications etc. (not altering text)
C1Pt. VIII (ss. 104–136) extended by S.I.s 1982/425, art. 3, 1984/187 art. 2; and extended with modifications by S.I. 1985/403, art. 3(1)
(1)Where an offence under this Act which is committed by a body corporate is proved to have been committed with the consent and connivance of, or to be attributable to any neglect on the part of, any director, manager, secretary or other similar officer of the body corporate, or any person who was purporting to act in any such capacity, he as well as the body corporate shall be guilty of that offence and shall be liable to be proceeded against and punished accordingly.
(2)In relation to a body corporate carrying on a retail pharmacy business as mentioned in subsection (1) of section 71 of this Act, the preceding subsection shall have effect in relation to a person who (not being such an officer of the body corporate as is mentioned in the preceding subsection)—
(a)is the superintendent referred to in subsection (1) of that section, or
(b)[F1in respect of any premises at or from which] the business is carried on, is the pharmacist referred to in [F2subsection (4)(b)] of that section who acts under the directions of the superintendent,
as if he were such an officer of the body corporate as is mentioned in the preceding subsection.
(3)In this section “director”, in relation to a body corporate established by or under any enactment for the purpose of carrying on under national ownership any industry or part of an industry or undertaking, being a body corporate whose affairs are managed by its members, means a member of that body corporate.
Textual Amendments
F1Words in s. 124(2)(b) substituted (1.12.2022) by The Pharmacy (Responsible Pharmacists, Superintendent Pharmacists etc.) Order 2022 (S.I. 2022/849), art. 1(3), Sch. 2 para. 21; S.I. 2022/1023, art. 2
F2Words in s. 124(2)(b) substituted (1.10.2009) by Health Act 2006 (c. 28), ss. 28(2), 83(7); S.I. 2008/2714, art. 2(a)
Modifications etc. (not altering text)
C2Pt. VIII (ss. 104–136) extended by S.I.s 1982/425, art. 3, 1984/187 art. 2; and extended with modifications by S.I. 1985/403, art. 3(1)
C3S. 124 extended (with modifications) (14.2.1994) by S.I. 1994/105, reg. 19, Sch.4
S. 124 applied (1.1.1995) by S.I. 1994/3142, reg. 18(2)
S. 124 applied (with modifications) (1.1.1995) by S.I. 1994/3144, reg.10, Sch. 4
S. 124 applied (31.3.1997) by S.I. 1997/322, reg. 34, Sch.5
C4Ss. 121-125 applied (with modifications) (1.5.2004) by Medicines for Human Use (Clinical Trials) Regulations 2004 (S.I. 2004/1031), regs. 1, 47, Schs. 9
C5Ss. 121-127 applied (with modifications) (30.10.2005) by Medicines (Traditional Herbal Medicinal Products for Human Use) Regulations 2005 (S.I. 2005/2750), regs. 1(a), 11, Schs. 4 (with Sch. 6)
C6Ss. 121-125 amendment to earlier affecting provision SI 2004/1031 reg. 47 Sch. 9 (29.8.2006) by Medicines for Human Use (Clinical Trials) Amendment Regulations 2006 (S.I. 2006/1928), regs. 1(1), 32
C7S. 124(1)(3) applied (with modifications) (3.4.1992) by S.I. 1992/605, reg. 2(1)(2),Sch.